Androgen deprivation increases p300 expression in prostate cancer cells

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3422-3430

  Heemers, Hannelore V ^a   Sebo, Thomas J ^a   Debes, Jose D ^a   Regan, Kevin M ^a   Raclaw, Kristin A ^a   Murphy, Linda M ^a   Hobisch, Alfred ^b   Culig, Zoran ^c   Tindall, Donald J ^a  

^a MAYO CLINIC   (United States)

^b General Hospital Feldkirch   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR BLOCKING AGENT; ANTIANDROGEN; BROXURIDINE; MESSENGER RNA; PROTEIN P300; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; E1A ASSOCIATED P300 PROTEIN; EP300 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; BIOSYNTHESIS; CELL GROWTH; DOWN REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

ANDROGENS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; E1A-ASSOCIATED P300 PROTEIN; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, MESSENGER; UP-REGULATION;

EID: 34248184635     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2836     Document Type: Article

References (37)

1. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
2. Roy-Burman P, Tindall DJ, Robins DM, et al. Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 2005;4:4-5.
3. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-97.
4. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88:2972-82.
5. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351: 1488-90.
6. Dehm SM, Tindall DJ. Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther 2005;5:63-74.
7. Heemers HV, Tindall DJ. Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr Cancer Ther Rev 2005;1:175-86.
8. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23: 175-200.
9. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002;62: 5632-6.
10. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen de AL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63:7638-40.
11. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142:4795-805.
12. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
13. Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 2005;65:5965-73.
14. Heemers HV, Verhoeven G, Swinnen JV. Androgen activation of the SREBP pathway: current insights. Mol Endocrinol 2006;20:2265-77.
15. Huang H, Zegarra-Moro OF, Benson D, Tindall DJ. Androgens repress bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene 2004;23:2161-76.
16. Catz SD, Johnson JL. Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. Oncogene 2001;20: 7342-51.
17. Shukla S, MacLennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of PI3K-Akt and NF-κB during prostate cancer progression in autochtonous transgenic mouse model. Prostate 2005;64:224-39.
18. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(κ)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005;64:160-7.
19. Chen CD, Sawyers CL. NF-κ B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22:2862-70.
20. Zelivianski S, Glowacki R, Lin MF. Transcriptional activation of the human prostatic acid phosphatase gene by NF-κB via a novel hexanucleotide-binding site. Nucleic Acids Res 2004;32:3566-80.
21. Wallner L, Dai J, Escara-Wilke J, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006;66: 3087-95.
22. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004;18:70-85.
23. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004;22:179-84.
24. Comuzzi B, Nemes C, Schmidt S, et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004;204:159-66.
25. Wang G, Jones SJ, Marra MA, Sadar MD. Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene 2006. Epub ahead of print.
26. Gong J, Zhu J, Goodman OB, Jr., et al. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 2006;25:2011-21.
27. 2 barrier to cancer. Cell Cycle 2006;5:831-6.
28. Kallakury BV, Sheehan CE, Rhee SJ, et al. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2. Cancer 1999;85:1569-76.
29. Maddison LA, Huss WJ, Barrios RM, Greenberg NM. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Prostate 2004;58: 335-44.
30. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891-5.
31. Egloff AM, Vella LA, Finn OJ. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006;66:6-9.
32. Yao TP, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998;93:361-72.
33. 1-S transition. Oncogene 2000;19:2430-7.
34. Albanese C, DAmico M, Reutens AT, et al. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999;274:34186-95.
35. Wasner M, Tschop K, Spiesbach K, et al. Cyclin B1 transcription is enhanced by the p300 coactivator and regulated during the cell cycle by a CHR-dependent repression mechanism. FEBS Lett 2003;536: 66-70.
36. Salsi V, Caretti G, Wasner M, et al. Interactions between p300 and multiple NF-Y trimers govern cyclin B2 promoter function. J Biol Chem 2003;278: 6642-50.
37. Agoulnik IU, Vaid A, Nakka M, et al. Androgens Modulate Expression of Transcription Intermediary Factor 2, an Androgen Receptor Coactivator whose Expression Level Correlates with Early Biochemical Recurrence in Prostate Cancer. Cancer Res 2006;66: 10594-602.